Circulating Endothelial Cells in Patients with Venous Thromboembolism and Myeloproliferative Neoplasms

被引:12
|
作者
Torres, Claudia [1 ,2 ]
Fonseca, Ana Mafalda [3 ]
Leander, Magdalena [1 ,2 ]
Matos, Rui [4 ]
Morais, Sara [2 ,4 ]
Campos, Manuel [2 ,4 ]
Lima, Margarida [1 ,2 ]
机构
[1] CHP, HSA, Serv Hematol Clin, Lab Citometria, Oporto, Portugal
[2] UP, UMIB, ICBAS, Oporto, Portugal
[3] UBI, CICS, Covilha, Portugal
[4] CHP, HSA, Serv Hematol Clin, Seccao Trombose & Hemostase, Oporto, Portugal
来源
PLOS ONE | 2013年 / 8卷 / 12期
关键词
PROGENITOR CELLS; TISSUE FACTOR; ESSENTIAL THROMBOCYTHEMIA; LEUKOCYTE ADHESION; ANTITHROMBIN-III; RISK-FACTORS; THROMBOSIS; BLOOD; HYDROXYUREA; PATHOPHYSIOLOGY;
D O I
10.1371/journal.pone.0081574
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Circulating endothelial cells (CEC) may be a biomarker of vascular injury and pro-thrombotic tendency, while circulating endothelial progenitor cells (CEP) may be an indicator for angiogenesis and vascular remodelling. However, there is not a universally accepted standardized protocol to identify and quantify these cells and its clinical relevancy remains to be established. Objectives: To quantify CEC and CEP in patients with venous thromboembolism (VTE) and with myeloproliferative neoplasms (MPN), to characterize the CEC for the expression of activation (CD54, CD62E) and procoagulant (CD142) markers and to investigate whether they correlate with other clinical and laboratory data. Patients and Methods: Sixteen patients with VTE, 17 patients with MPN and 20 healthy individuals were studied. The CEC and CEP were quantified and characterized in the blood using flow cytometry, and the demographic, clinical and laboratory data were obtained from hospital records. Results: We found the CEC counts were higher in both patient groups as compared to controls, whereas increased numbers of CEP were found only in patients with MPN. In addition, all disease groups had higher numbers of CD62E+ CEC as compared to controls, whereas only patients with VTE had increased numbers of CD142+ and CD54+ CEC. Moreover, the numbers of total and CD62+ CEC correlated positively with the white blood cells (WBC) counts in both groups of patients, while the numbers of CEP correlated positively with the WBC counts only in patients with MPN. In addition, in patients with VTE a positive correlation was found between the numbers of CD54+ CEC and the antithrombin levels, as well as between the CD142+ CEC counts and the number of thrombotic events. Conclusions: Our study suggests that CEC counts may reveal endothelial injury in patients with VTE and MPN and that CEC may express different activation-related phenotypes depending on the disease status.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Circulating endothelial cells in venous thromboembolism
    Campos, M.
    Torres, C.
    Matos, R.
    Morais, S.
    Lima, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 651 - 651
  • [2] Management of venous thromboembolism in myeloproliferative neoplasms
    Barbui, Tiziano
    De Stefano, Valerio
    [J]. CURRENT OPINION IN HEMATOLOGY, 2017, 24 (02) : 108 - 114
  • [3] Soluble endothelial cell molecules and circulating endothelial cells in patients with venous thromboembolism
    Torres, Claudia
    Matos, Rui
    Morais, Sara
    Campos, Manuel
    Lima, Margarida
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (08) : 589 - 595
  • [4] Are circulating endothelial cells increased in patients with venous thromboembolism and are levels greater in patients with underlying malignancy and venous thromboembolism?
    Dawar, J. R.
    Rose, P. E.
    Chant, I. D.
    Gordge, M.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 3 - 3
  • [5] Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
    Valerio De Stefano
    Guido Finazzi
    Tiziano Barbui
    [J]. Blood Cancer Journal, 8
  • [6] Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
    De Stefano, Valerio
    Finazzi, Guido
    Barbui, Tiziano
    [J]. BLOOD CANCER JOURNAL, 2018, 8
  • [7] A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms
    Hamulyak, Eva N.
    Daams, Joost G.
    Leebeek, Frank W. G.
    Biemond, Bart J.
    te Boekhorst, Peter A. W.
    Middeldorp, Saskia
    Lauw, Mandy N.
    [J]. BLOOD ADVANCES, 2021, 5 (01) : 113 - 121
  • [8] CIRCULATING ENDOTHELIAL CELLS (CEC) AS A SURROGATE MARKER FOR EVOLUTION IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
    Antelo, M. L.
    Ramirez, N.
    Angona, A.
    Alvarez-Larran, A.
    Perez-Valderrrama, E.
    Mansilla, C.
    Ciaurriz, M.
    Rifon, J.
    Olavarria, E.
    Rodriguez-Calvillo, M.
    [J]. HAEMATOLOGICA, 2015, 100 : 522 - 522
  • [9] Machine Learning to Predict Risk of Venous Thromboembolism Among Patients with Myeloproliferative Neoplasms in the Intensive Care Unit
    Khosla, Atulya Aman
    Batra, Nitya
    Singh, Rohit
    Jatwani, Karan
    Batra, Akshee
    Zhang, Yanjia
    Zhang, Zhenwei
    Ahmed, Md Ashfaq
    Roy, Mukesh
    Ramamoorthy, Venkataraghavan
    Rubens, Muni
    Saxena, Anshul
    Herrera, Diego Adrianzen
    [J]. BLOOD, 2023, 142
  • [10] High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
    V De Stefano
    M Ruggeri
    F Cervantes
    A Alvarez-Larrán
    A Iurlo
    M L Randi
    E Elli
    M C Finazzi
    G Finazzi
    E Zetterberg
    N Vianelli
    G Gaidano
    E Rossi
    S Betti
    I Nichele
    D Cattaneo
    M Palova
    M H Ellis
    R Cacciola
    A Tieghi
    J C Hernandez-Boluda
    E Pungolino
    G Specchia
    D Rapezzi
    A Forcina
    C Musolino
    A Carobbio
    M Griesshammer
    E Sant’Antonio
    A M Vannucchi
    T Barbui
    [J]. Leukemia, 2016, 30 : 2032 - 2038